Medical, surgical, Mohs and cosmetic dermatology bill under four different rule sets on the same schedule, and the seams between them are where a practice quietly writes off six figures a year.
Get a free revenue cycle assessmentDermatology revenue cycle management is the full financial process for a dermatology practice, from eligibility and prior authorization before the visit through coding, claim submission, denial appeals, payment posting and patient collections. Medical billing is one stage inside it, the part that builds and sends the claim, while revenue cycle management owns everything that happens before and after.
Most specialties bill one kind of service. Dermatology bills four, often inside a single appointment.
A patient comes in for acne, mentions a changing mole, and leaves having had an E/M service, a punch biopsy, a specimen sent to pathology and a cosmetic filler quote. That encounter touches E/M documentation rules, the National Correct Coding Initiative edits that bundle minor procedures into same day visits, the pathology component split, and the statutory exclusion governing cosmetic work. Each fails differently.
At 35 to 45 patients a day, a pattern wrong on one visit in eight is wrong several thousand times a year. Dermatology leaks through repetition, not catastrophe, which is why a denial report showing only totals hides the pattern costing the money.
Lesion removals, phototherapy and biologics sit in categories payers treat as potentially elective, and multiple lesion removals attract reductions and documentation requests. Proving medical necessity falls to a note written at the point of care, months before anyone reads the denial.
Any three of these together mean the revenue cycle, not the front desk, is the problem.
A free dermatology revenue cycle assessment reads your last 90 days of remits and tells you which are true.
Recognise three or more of these in your own numbers and the problem is the process, not the payer.
Get a free assessmentDermatology practices sort by service line mix, not size, and the mix decides which part of the cycle breaks.
A practice running all six needs six controls.
Google asks for seven steps. Here they are, each with the failure specific to a skin practice.
The failure: nobody checks whether the reason for the visit is a covered benefit, so a cosmetic consultation registers as insurance.
The failure: approval covers a drug, a site and a date range, and one of the three drifts before treatment.
The failure: cosmetic and covered services share one payment screen, so money lands on the wrong ledger.
The failure: the code comes from the plan rather than the final measurement, and the note never records diameter plus margin.
The failure: generic scrubber rules with no dermatology bundling logic, so NCCI conflicts and unit-cap breaches pass through.
The failure: bundled denials are written off as correct because nobody tests whether the E/M was separately identifiable.
The failure: the ten-day global period makes patients think a follow up was free, so the balance that does exist gets disputed.
Nobody ranking for this search has tabulated where dermatology money goes. The dollars column is modelled for a three provider practice collecting about $2.4 million across roughly 16,000 claims. The findings are measured; the dollars are modelled from them.
| Leak point | Codes or rule | What goes wrong | Annual dollars at risk | Luxen audit finding |
|---|---|---|---|---|
| Same-day visit plus minor procedure | Modifier 25; NCCI Policy Manual Chapter 1 | E/M bundled into the procedure, though a separately identifiable service is payable and needs no different diagnosis. | $48,000 | Same-day procedures with an E/M visit were denied for modifier 25 on 14% of claims |
| Lesion excision sizing | 11400 to 11406 and 11600 to 11606 | Code taken from the pre-operative estimate, not diameter plus margin measured before excision. | $21,000 | Excision codes were selected before final lesion size was documented on 10% of claims |
| Destruction unit caps | 17000, 17003, 17004 | 17003 may be billed thirteen times per date of service and 17004 once. Unenforced caps cause rejections or under-reporting. | $14,000 | Actinic keratosis destruction was reported outside the 17003 and 17004 unit rules on 9% of sessions |
| Mohs stages and blocks | 17311 to 17315, add-ons carry ZZZ | Histology log and claim reconciled separately, so additional blocks go unbilled. | $26,000 | Additional Mohs blocks under 17315 were documented but never billed on 12% of multi-block cases |
| Global period follow ups | 010 global on the 11400, 11600, 17000 and 17110 families; modifiers 24, 58, 78, 79 | Unrelated visits inside ten days written off as bundled; staged procedures billed without modifier 58. | $17,000 | Unrelated visits inside a 010 global period were billed without modifier 24 on 11% of post-procedure encounters |
| Dermatopathology component split | 88304 and 88305, PC/TC indicator 1; 42 CFR 414.50 | Components billed to the wrong entity, specimens counted per container, readings above the anti-markup limit. | $23,000 | Professional and technical components disagreed between the lab and the practice claim on 7% of specimens |
| Cosmetic and non-covered services | Modifier GY with a voluntary notice; ABN form CMS-R-131 | Cosmetic work is statutorily excluded, so a mandatory ABN is not required and modifier GA is wrong. | $19,000 | Statutorily excluded cosmetic claims carried no GY modifier on 16% of submissions |
We will tell you which of these leaks is open in your practice, free, in 30 minutes.
Book the reviewEvery competing page names these metrics and none publishes a target. Sourcing differs by row. No federal dataset publishes days in AR, net collection rate, clean claim rate or cost to collect by specialty, so where no federal figure exists the Typical column reports what Luxen measured across 410 practice billing reviews and says so. The Target column is Luxen client data across 38 practices, January 2024 to June 2026.
| Metric | Definition | Typical | Target |
|---|---|---|---|
| Days in AR | Days from date of service to payment | 54 days. No federal benchmark; Luxen billing reviews median | 33 or fewer |
| Net collection rate | Payments divided by allowed amount after adjustments | 91.4%. No federal benchmark; Luxen client baseline | 97.8% |
| Clean claim rate | Claims accepted on first submission | 89.6%. No federal benchmark; Luxen client baseline | 97.3% |
| First-pass denial rate | Claims denied on first adjudication | 6.55% of Medicare fee-for-service payments were improper in reporting year 2025 (CMS CERT). Luxen measured 14.2% at onboarding | 6.1% or lower |
| Cost to collect | Fully loaded billing cost as a share of collections | 7.9% of collections for in-house teams under $2M, across 96 practices that shared payroll data | 3% to 6% |
| Modifier 25 denial rate | Same-day E/M with a minor procedure denied as bundled | 14% across 8,400 dermatology claims. No federal benchmark | Below 4% |
Typical values come from the named federal source in the table intro. Target values come from Luxen client data.
Dermatology has no utilization review department the way a behavioral health program does, so authorization failures go unnoticed until the claim denies.
The drug, the site of administration and the date range all have to be live. Risankizumab bills under J2327, tildrakizumab under J3245, ustekinumab under J3357 subcutaneous or J3358 intravenous, and J3247 covers secukinumab intravenous only. Ixekizumab is self administered, generally excluded from Part B and has no dedicated permanent J-code, so it routes through the pharmacy benefit and never reaches a medical claim. Practices treating every biologic as a medical benefit lose the ones that are not.
Separately payable Part B drugs from single-dose containers need modifier JW for discarded amount or JZ for zero discarded amount. JZ has been required since July 1, 2023, and claims missing the appropriate modifier have been returnable as unprocessable since October 1, 2023. Neither applies to multi-dose vials.
Codes 96900, 96910, 96912 and 96913 carry an XXX global indicator; excimer laser under 96920, 96921 and 96922 carries 000 and is banded by treated surface area. Authorizations cover a number of sessions over a window, and the window closes whether or not the patient attended. The fix is an authorization register keyed to patient, drug, site, units remaining and expiry date, visible to whoever books. Luxen runs it inside your system as eligibility and prior authorization.
This is the mechanic that defines dermatology revenue, and not one page ranking for this search names it.
Modifier 25 reports a significant, separately identifiable E/M service by the same clinician on the same day as a procedure. The National Correct Coding Initiative policy manual is explicit that the decision to perform a minor surgical procedure is included in the payment for that procedure and is not separately reportable. The exception is an E/M service unrelated to that decision. The part most practices get wrong: the manual states the E/M may carry the same or a different diagnosis as the procedure. A different diagnosis is not required. Staff trained to hunt for a second diagnosis suppress payable claims; practices appending it to everything invite an audit.
Biopsies under 11102 through 11107 carry 000, with add-ons at ZZZ. Excisions in the 11400 and 11600 families and destruction under 17000, 17004, 17110 and 17111 carry 010. Mohs base stages 17311 and 17313 are 000, with additional stages and blocks as ZZZ add-ons. Inside a 010 window the global package covers follow up visits, dressing changes and suture removal, but not visits unrelated to the surgical diagnosis, which are payable with modifier 24. A staged procedure planned at the time of the original takes modifier 58; an unrelated one takes 79.
CMS asks for the specific X modifier rather than 59: XE separate encounter, XS separate structure, XP separate practitioner, XU unusual non-overlapping service, and states 59 should be used only when no more specific modifier applies. On a lesion-heavy schedule, XS carries most of the load. See medical coding.
Every competing page mentions cosmetic versus medical. None names the instrument that resolves it.
A cosmetic procedure is not something Medicare might cover and then denies as unreasonable. It is something Medicare never covers, and that changes the paperwork. An Advance Beneficiary Notice of Non-coverage, form CMS-R-131, is mandatory when a normally covered item is expected to be denied as not reasonable and necessary. For a service that is never a Medicare benefit it is not required; a voluntary notice may be issued as a courtesy and the patient need not sign it.
Cosmetic work should be quoted, collected and posted on a self pay ledger that never touches the insurance workflow; when the two share a payment screen the practice generates refunds and rebills that cost more to unwind than the original charge. The grey zone is decided by the indication recorded at the point of care, not the code chosen afterwards. Our patient billing workflow keeps the ledgers apart from the first quote.
The specimen is where dermatology stops being one business and becomes two.
Surgical pathology codes 88304 and 88305 carry a PC/TC indicator of 1, so professional and technical components can be billed separately using modifier 26 for the reading and TC for the technical work. A practice with an in-house lab bills both; one that sends out bills neither, or only the professional component if its own dermatopathologist reads the slides. When the practice claim and the lab claim disagree, one denies as a duplicate and nobody notices which.
The NCCI policy manual defines the unit of service for codes 88300 through 88309 as the specimen, meaning tissue submitted for individual and separate attention, examination and diagnosis. Three lesions in three containers for three diagnoses are three specimens; three fragments of one lesion in one container are one.
Where the practice bills for a reading purchased from an outside physician, 42 CFR 414.50 limits payment to the lowest of the performing supplier's net charge, the billing practice's actual charge, or the fee schedule amount allowable had the performing supplier billed directly, and the billing entity must identify the performing supplier and state that net charge or no payment is made. Results also return days after the procedure, so unless something reconciles the accession log against the claim file, charge lag is where specimens disappear. Same discipline full service medical billing applies to every charge created after the patient leaves.
Dataset: 8,400 dermatology claims drawn from the Luxen claim audit of 61,400 claims, January 2025 to June 2026. We counted, claim by claim, whether the code billed matched the documentation and whether a payable service went unbilled.
No competing page in the top ten names modifier 25, a global period, a Mohs block or the pathology component split.
A four provider dermatology group running medical, surgical and a small cosmetic line came to Luxen with 31% of AR past 90 days and a first-pass denial rate of 15.8%, most of it in a bundled bucket nobody had broken down. Over eight months, January to August 2026, inside their existing system:
Their administrator's summary: the denials were never the problem, the fact that nobody had sorted them by cause was.
Mohs stages, tissue blocks, and pathology documentation were not consistently reviewed together. Luxen introduced a case-level audit, reduced Mohs billing errors from 12.6% to 3.1%, and recovered $48,900.
Practice Administrator, dermatology and Mohs surgery group
Cosmetic services and insurance-covered dermatology procedures were posted through the same workflow. Luxen separated patient-pay and insurance charges, reducing rebilling and refund cases by 68%.
Revenue Cycle Manager, multi-location dermatology practice
Worked for a three provider practice collecting $2.4 million a year across roughly 16,000 claims, a blended $150 per claim. Substitute your own numbers; the basis matters more than the answer.
Median days in AR dropped from 54 to 33, a 21 day improvement. Every 10 days removed from AR released a median $41,000 in cash for practices collecting $1.5 million to $3 million a year. 21 divided by 10, times $41,000, is $86,100. One-time release, not recurring.
First-pass denial rate fell from 14.2% to 6.1%, removing 8.1 points. 16,000 claims at 8.1% is 1,296 that no longer deny on first pass. Since 19% of denied claims were never reworked or appealed, 1,296 times 19% is 246 claims previously abandoned. At $150 each, $36,900 a year, recurring.
If same-day E/M plus procedure is 30% of encounters, that is 4,800 claims, and at the audited 14% denial rate 672 deny. Appeals filed by Luxen were overturned 68% of the time, giving 457 recovered claims. At an assumed $105 allowed for the E/M component, $47,985 a year.
Recurring gain of $84,885 against a fee of 5% of collections on $2.4 million, or $120,000. In-house at 7.9% of collections costs $189,600, so the fee is $69,600 cheaper before any recovery is counted.
Want this arithmetic run on your own collections and denial rate?
Run my numbersLuxen charges a percentage of what we collect. For dermatology the range is 3% to 6% of collections, set by claim volume and average claim value, service line mix, and the state of the AR we inherit. A medical-only practice sits lower than one running Mohs, an in-house lab and a cosmetic line. Legacy AR is quoted separately where the backlog needs its own queue.
Included at every point: coding, claim submission, denial management and appeals, payment posting, AR follow up, patient statements, and monthly reporting on days in AR, net collection rate, clean claim rate and denial reasons. No setup fee, no exit fee, month to month with 30 days notice. Credentialing is priced separately, per provider and per payer.
Annual figures for a three provider dermatology practice collecting about $2.4 million. The in-house column uses fully loaded cost measured across 96 practices that shared payroll data.
| Line item | In-house | Luxen |
|---|---|---|
| Billing and coding staff, fully loaded | $142,000 for two FTE including benefits and payroll tax | Included |
| Billing software and clearinghouse | $14,400 | Included; we work in your existing system |
| Coding certification and training | $6,800 | Included |
| Denial rework and appeals capacity | Absorbed by the same two FTE, which is why 19% of denied claims were never reworked or appealed | Included, worked by root cause |
| Cover for vacancy and turnover | Open biller roles took a median of 67 days to fill | No single point of failure |
| Total cost as a share of collections | 7.9% | 3% to 6% |
Keep it in-house if you have a tenured certified coder who knows dermatology, a named second person to cover them, and a denial report you already read monthly by root cause. Outsource when the denial bucket has no owner, when one person's holiday stops the cash flow, or when you cannot say what your clean claim rate was last month. Comparisons sit on our medical billing companies directory.
People ask which are the top five revenue cycle management companies in the United States. Wrong question: the answer changes by specialty and practice size, and every published list is written by someone on it. Score candidates instead.
Score each zero to three. Under thirteen of eighteen is a vendor who will manage your claims but not your revenue.
You have an incumbent. That is the normal case, and practices worry about it more than they need to.
Nothing changes in your systems. We work inside your existing EHR and practice management software: no migration, no data conversion, no clinical retraining. Signed business associate agreement, then access, then a parallel period where legacy AR keeps being worked while new claims flow through our queues. Across 38 client practices, median time from signed BAA to first claims worked was 9 business days, and first recovered payments arrived a median of 17 days after work began.
The legacy AR question matters more than the timeline. Ask any candidate in writing who works the claims your current biller gave up on. We recovered 61% of the dollar value of claims aged 90 to 180 days that practices had stopped working. See denials and AR recovery.
Dermatology runs on a short list of systems: the two dermatology-specific platforms most practices use, plus Nextech, eClinicalWorks or DrChrono, and a pathology LIS where there is an in-house lab. We work inside whichever you have.
Automate prediction last. A denial you prevented is worth more than a denial you forecast.
Eligibility and benefit verification, prior authorization, point-of-service collection, charge capture and coding, claim scrubbing and submission, remittance and denial management, then patient balance and AR follow up. In dermatology the fourth and sixth break most often: lesion sizing and specimen counts are decided at the point of care, while bundled denials are written off at the point of payment.
Any published ranking is written by someone who appears on it, and the right answer changes by specialty and practice size, so score candidates against criteria instead. Ask for their modifier 25 denial rate on dermatology claims, a denial report broken down by root cause rather than payer, and the fee basis in writing. 44% of practice managers could not name the fee basis in their current billing contract.
Patient, Provider, Payer and Process. In dermatology the Provider element carries the most risk, because the code depends on decisions made at the point of care: the greatest clinical diameter plus the margin required for complete excision, measured before excision, and whether the E/M service was significant and separately identifiable.
Luxen charges 3% to 6% of collections for dermatology, set by claim volume, service line mix and the state of the legacy AR. For comparison, fully loaded in-house billing cost 7.9% of collections for practices under $2 million, across 96 practices that shared payroll data. No setup fee, no exit fee, month to month with 30 days notice.
Median time from signed business associate agreement to first claims worked was 9 business days across 38 client practices, and first recovered payments arrived a median of 17 days after work began. Denial improvement shows inside 90 days: first-pass denial rate fell from 14.2% to 6.1%. Days in AR takes longer because old accounts must age out.
Appending or withholding modifier 25 on the wrong test, since the NCCI policy manual states the E/M service may carry the same diagnosis as the procedure and a different diagnosis is not required. Choosing an excision code before the lesion is measured. Ignoring the 010 global period on the 11400, 11600, 17000 and 17110 families. Billing cosmetic work with modifier GA when it is statutorily excluded and needs GY.
State Medicaid programmes differ on coverage for benign lesion destruction and phototherapy, so confirm your own: see Nevada and Oregon. New providers go through credentialing; a worked recovery sits in our dental practice case study.
A free 30 minute review of your AR ageing and denial reasons. We tell you what is recoverable and what it would take. No deck, no commitment, no fee.
Book a free revenue cycle assessment%20(1).avif)
